AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Director's Dealing May 6, 2022

3232_dirs_2022-05-06_8ebfb56d-b461-4239-9fd1-e7f3dcc73f0e.html

Director's Dealing

Open in Viewer

Opens in native device viewer

Disclosure 408374

Orion - Managers' transactions

Orion Corporation: Managers’ transactions – Eija Ronkainen

ORION CORPORATION

MANAGERS’ TRANSACTIONS

6 MAY 2022 at 16.00 EEST

Orion Corporation: Managers’ transactions – Eija Ronkainen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Eija Ronkainen

Position: Member of the Board/Deputy member

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 14512/4/4

____________________________________________

Transaction date: 2022-05-05

Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)

Instrument type: SHARE

ISIN: FI0009014377

Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details

(1): Volume: 485 Unit price: 0.00000 EUR

Aggregated transactions

(1): Volume: 485 Volume weighted average price: 0.00000 EUR

Orion Corporation

Timo Lappalainen



President and CEO
Olli Huotari



SVP, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Talk to a Data Expert

Have a question? We'll get back to you promptly.